SCHEMBL13966414

SCHEMBL13966414

COc1ccc(CNc2ncnc3c2ncn3[C@@H]2O[C@H](CO)[C@@H]3OC(C)(C)OC32)cc1

nearest known ligand 0.75

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ PI4KA P42356 1/20 0.61
▸ PI4K2B Q8TCG2 1/20 0.61
▸ PI4K2A Q9BTU6 1/20 0.61
▸ PI4KB Q9UBF8 1/20 0.61
▸ SLC29A1 Q99808 4/20 0.58
▸ TP53 P04637 1/20 0.57
▸ ADORA3 P0DMS8 1/20 0.57
▸ TDP1 Q9NUW8 1/20 0.57
▸ ADORA1 P30542 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13975624 1.00 PI4KA (0.61) PI4KAPI4K2BPI4K2API4KBSLC29A1
SCHEMBL17371116 1.00 PI4KA (0.61) PI4KAPI4K2BPI4K2API4KBSLC29A1
SCHEMBL21139430 1.00 PI4KA (0.61) PI4KAPI4K2BPI4K2API4KBSLC29A1
SCHEMBL20435006 0.96 PI4KA (0.56) PI4KAPI4K2BPI4K2API4KBSLC29A1
SCHEMBL26292145 0.96 PI4KA (0.56) PI4KAPI4K2BPI4K2API4KBSLC29A1
SCHEMBL20435009 0.96 PI4KA (0.56) PI4KAPI4K2BPI4K2API4KBSLC29A1
SCHEMBL26292390 0.92 PI4KA (0.60) PI4KAPI4K2BPI4K2API4KBSLC29A1
SCHEMBL13966415 0.92 CCNB2 (0.52) PI4KAPI4K2BPI4K2API4KBSLC29A1
SCHEMBL13238334 0.91 PI4KA (0.65) PI4KAPI4K2BPI4K2API4KBSLC29A1
SCHEMBL20434974 0.90 PI4KA (0.64) PI4KAPI4K2BPI4K2API4KBSLC29A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753432-B2 Compound with analgesic effect for use in prevention and treatment of pain ACADEMIA SINICA (TW) 2023-09-12 — — US disclosed
US-20150374737-A1 Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases ACADEMIA SINICA (TW) 2015-12-31 — — US disclosed
US-20120295863-A1 Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases ACADEMIA SINICA (TW) 2012-11-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150374737-A1 Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases ADORA2A, ADORA1, ADORA3 PI4KA 2167/4885PI4K2B 2225/4885PI4K2A 1699/4885
US-11753432-B2 Compound with analgesic effect for use in prevention and treatment of pain ADORA2B, ADORA1, ADORA3 PI4KA 3007/4885PI4K2B 3300/4885PI4K2A 2830/4885
US-20120295863-A1 Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases ADORA2A, ADORA1, ADORA3 PI4KA 2167/4885PI4K2B 2225/4885PI4K2A 1699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback